Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience
- 1 June 2016
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 16 (6) , e79-e84
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Treatment of Immunoglobulin Light Chain AmyloidosisMayo Clinic Proceedings, 2015
- Upfront CyBorD in AL amyloidosisBlood, 2015
- Guidelines on the management of AL amyloidosisBritish Journal of Haematology, 2014
- Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patientsLeukemia, 2014
- Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III)Haematologica, 2014
- New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival OutcomesJournal of Clinical Oncology, 2012
- Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosisBlood, 2012
- Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survivalBlood, 2012
- Best use of cardiac biomarkers in patients with AL amyloidosis and renal failureAmerican Journal of Hematology, 2012
- Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and AmyloidosisAmerican Journal of Hematology, 2005